BKM120 in Advanced, Metastatic, or Recurrent Endometrial Cancers

Summary

This is a phase II open label fixed dose study in subjects with advanced, metastatic, or refractory endometrial or ovarian, fallopian tube, or primary peritoneal cancer with PI3 kinase pathway activation as demonstrated by PIK3CA gene mutation, PTEN gene mutation, or PTEN null/low protein expression.

Timeline

Start

2014-05

Primary completion

2014-07

Completion

2014-07

Drugs

Indications